Drug Database · Clinicians

Thiocolchicoside

Brands (1) Thiozz-8Show all

Muscle relaxant PH FDA category

Rx · Prescription drug1 PH product Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Contraindications

  • Pregnancy and breastfeeding
  • Women of childbearing potential not using effective contraception
  • Children (under 16 years)
  • Long-term treatment of chronic conditions (not recommended)
renalcarematters.com, reviewed

Dosing: Adult

  • Adjuvant treatment of painful muscle contractures in acute spinal conditions (16 years and older): Oral: up to 8 mg every 12 hours for at most 7 days. Intramuscular: up to 4 mg every 12 hours for at most 5 days
renalcarematters.com, reviewed

Dosing: Altered kidney function

Thiocolchicoside is a muscle relaxant whose metabolite (3-demethylthiocolchicine) caused aneuploidy in preclinical studies, so the European Medicines Agency restricted it in 2014 to short courses in adults and adolescents 16 years and older. The European review gives no kidney-impairment dosing. It has no US FDA label.

Kidney function measure: The EMA review does not address kidney impairment; bands shown on creatinine clearance (CrCl).

Show full dosing details
CrCl ≥60 mL/min
Oral: maximum 8 mg every 12 hours for no more than 7 consecutive days. Intramuscular: maximum 4 mg every 12 hours for up to 5 days (EMA 2014).
CrCl 30–59 mL/min
The EMA review gives no kidney dosing, and no kidney pharmacokinetic data were retrieved. Use with caution and specialist judgment.
CrCl 15–29 mL/min
The EMA review gives no kidney dosing, and no kidney pharmacokinetic data were retrieved. Use with caution and specialist judgment.
CrCl <15 mL/min (not on dialysis)
The EMA review gives no kidney dosing, and no kidney pharmacokinetic data were retrieved. Use with caution and specialist judgment.
Hemodialysis (intermittent)
Not studied in dialysis; no dose given.
Peritoneal dialysis
Not studied in dialysis; no dose given.
CRRT
Not studied in dialysis; no dose given.
  • Dialyzable? Not stated.
  • Monitoring Do not exceed dose or duration limits (oral 8 mg every 12 hours for up to 7 days; IM 4 mg every 12 hours for up to 5 days); aneuploidy risk from a metabolite. Pregnancy status: contraindicated in pregnancy, breastfeeding and in women of childbearing potential without effective contraception. Do not exceed the dose or duration limits (EMA 2014).
Children (kidney dosing)
eGFR ≥60
Not for children under 16; no pediatric kidney data.
eGFR 30–59
Not for children under 16; no pediatric kidney data.
eGFR 15–29
Not for children under 16; no pediatric kidney data.
eGFR <15 (not on dialysis)
Not for children under 16; no pediatric kidney data.
Hemodialysis (intermittent)
Not for children under 16; no pediatric kidney data.
Peritoneal dialysis
Not for children under 16; no pediatric kidney data.
CRRT
Not for children under 16; no pediatric kidney data.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: EMA product information (January 17, 2014). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Adults and adolescents 16 years and older only (EMA 2014).
Usual dose
16 years and older: adult limits.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Orodispersible tablet: 8 mg

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Thiocolchicoside as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Thiocolchicoside
Package insert
Thiozz-8Thiocolchicoside
8 mg Orodispersible TabletAlu/Alu Blister Pack x 10's (Box of 10's)
Rx
Ipca Laboratories Ltd.India
Blue Global (FZE)
DR-XY48339
Sep 6, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Adverse reactions

Serious

  • Aneuploidy risk from a metabolite (preclinical): possible teratogenicity, miscarriage, impaired male fertility
renalcarematters.com, reviewed

Monitoring parameters

  • Do not exceed dose or duration limits (oral 8 mg every 12 hours for up to 7 days; IM 4 mg every 12 hours for up to 5 days); aneuploidy risk from a metabolite. Pregnancy status: contraindicated in pregnancy, breastfeeding and in women of childbearing potential without effective contraception. Do not exceed the dose or duration limits (EMA 2014). Kidney
  • Dose and duration limits (aneuploidy risk)
  • Pregnancy status and contraception
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Active metabolites3-demethylthiocolchicine (SL59.0955), linked to aneuploidy
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. European Medicines Agency. Thiocolchicoside Article 31 referral (2014) [EMA product information, January 17, 2014; no US FDA label]. https://www.ema.europa.eu/en/medicines/human/referrals/thiocolchicoside-containing-medicines
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. European Medicines Agency. (2014). Thiocolchicoside-containing medicines: Article 31 referral (Commission decision January 17, 2014; EMA/706409/2013). https://www.ema.europa.eu/en/medicines/human/referrals/thiocolchicoside-containing-medicines

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .